Valuation: Senores Pharmaceuticals Limited

Market Cap 52.22B 550M 493M 453M 411M 767M 782M 5.4B 2.17B 27.47B 2.06B 2.02B 86.63B P/E 2027 *
36.6x
P/E 2028 * 23.3x
Enterprise Value 52.22B 550M 493M 453M 411M 767M 782M 5.4B 2.17B 27.47B 2.06B 2.02B 86.63B EV / Sales 2027 *
5.92x
EV / Sales 2028 * 4.41x
Free-Float
45.07%
Yield 2027 *
0.67%
Yield 2028 * 1.01%
10-29 Senores Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 CI
08-26 Senores Pharmaceuticals Limited Announces Executive and Board Appointments, Effective August 26, 2026 CI
08-26 Senores Pharmaceuticals Limited Approves Proposal of Incorporation of Wholly-Owned Subsidiary in Mexico and Canada CI
07-27 Senores Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-26 9,233,746 Equity Shares of Senores Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 27-JUN-2026. CI
05-14 Senores Pharmaceuticals Limited Announces Resignation of Vinay Kumar Mishra as Company Secretary and Compliance Officer, Effective June 10, 2026 CI
05-14 Senores Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-14 Senores Pharmaceuticals March-quarter consol net profit 316.1 million rupees RE
04-03 Senores Pharmaceuticals announces strategic joint venture in United States RE
03-27 Senores Pharmaceuticals Limited announced that it has received INR 237.51 million in funding from Renosen Pharmaceuticals Private Limited and other investors CI
01-20 Senores Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-20 Senores Pharmaceuticals Dec-quarter Consol Net Profit 316.6 Million Rupees RE
01-07 Senores Pharmaceuticals board approves issuance of warrants up to 950 million rupees RE
1 day-7.00%
1 week-5.71%
Current month-18.18%
1 month-19.22%
3 months-13.99%
6 months+25.50%
Current year+37.91%
1 week 1,053.4
Extreme 1053.4
1,341
1 month 1,053.4
Extreme 1053.4
1,424
Current year 706
Extreme 706
1,599
1 year 706
Extreme 706
1,599
3 years 435.25
Extreme 435.25
1,599
5 years 435.25
Extreme 435.25
1,599
10 years 435.25
Extreme 435.25
1,599
Manager TitleAgeSince
Chief Executive Officer 41 2021-10-14
Director of Finance/CFO 63 2019-12-31
Compliance Officer - 2026-08-25
Director TitleAgeSince
Director/Board Member 41 2021-10-14
Chairman 63 2024-02-09
Director/Board Member 60 2018-05-14
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Buy

Chief Operating Officer

550 0.0012%
2/27/25 Buy

Chief Operating Officer

1,000 0.0022%
2/27/25 Buy

Chief Operating Officer

1,000 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-7.00%-5.71%+46.55% - 590M
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.22%+1.44%+47.65%+85.17% 417.74B
Weighted average by Cap. +2.04%+3.04%+53.35%+100.42%

Financials

2027 *2028 *
Net sales 8.82B 92.89M 83.19M 76.53M 69.34M 130M 132M 913M 366M 4.64B 349M 341M 14.63B 11.83B 125M 112M 103M 93M 174M 177M 1.22B 491M 6.22B 468M 458M 19.62B
Net income 1.76B 18.48M 16.55M 15.23M 13.8M 25.79M 26.27M 182M 72.89M 923M 69.37M 67.89M 2.91B 2.33B 24.53M 21.97M 20.21M 18.31M 34.22M 34.86M 241M 96.72M 1.23B 92.05M 90.09M 3.86B
Net Debt - -
Projected Income Statement - Annual - Senores Pharmaceuticals Limited
Logo Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is an India-based company. The Company is engaged in the development and manufacturing of a pharmaceutical product. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Acetaminophen + Butalbital Tablet, Candesartan Cilexetil + HCTZ Tablet, Losartan Potassium Tablet, Chlorzoxazone Tablet, Clomiphene Tablet, Deferiprone Tablet, Diltiazem ER Capsule, Enalapril Maleate Tablet, Escitalopram Tablet, Irbesartan Tablet, Olmesartan Medoxomil Tablet and others. It supplies affordable Active Pharmaceutical Ingredients (API) to generic formulations manufacturers. Its product API includes Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Immunosen - Human Normal Immunoglobulin, Senumin - Human Normal Albumin and others.
Employees
368
Date Price Change Volume
26-10-29 ₹1,133.90 -7.00% 2,316,991
26-10-29 ₹1,219.20 -7.94% 1,074,001
26-10-28 ₹1,324.30 +1.01% 186,875
26-10-27 ₹1,311.00 +5.26% 204,236
26-10-26 ₹1,245.50 +2.48% 158,092
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Senores Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1,133.90INR
Average target price
1,613.60INR
Spread / Average Target
+42.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Senores Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. SENORES Stock